IBDEI09V ; ; 09-MAY-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 09, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13229,1,8,0)
 ;;=8^Evan's Syndrome
 ;;^UTILITY(U,$J,358.3,13229,2)
 ;;=^332747
 ;;^UTILITY(U,$J,358.3,13230,0)
 ;;=287.41^^83^834^20
 ;;^UTILITY(U,$J,358.3,13230,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13230,1,1,0)
 ;;=1^287.41
 ;;^UTILITY(U,$J,358.3,13230,1,8,0)
 ;;=8^Posttransfusion Purpura
 ;;^UTILITY(U,$J,358.3,13230,2)
 ;;=^339609
 ;;^UTILITY(U,$J,358.3,13231,0)
 ;;=287.49^^83^834^18
 ;;^UTILITY(U,$J,358.3,13231,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13231,1,1,0)
 ;;=1^287.49
 ;;^UTILITY(U,$J,358.3,13231,1,8,0)
 ;;=8^Oth Secondary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,13231,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,13232,0)
 ;;=287.8^^83^834^19
 ;;^UTILITY(U,$J,358.3,13232,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13232,1,1,0)
 ;;=1^287.8
 ;;^UTILITY(U,$J,358.3,13232,1,8,0)
 ;;=8^Oth Spec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,13232,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,13233,0)
 ;;=287.9^^83^834^27
 ;;^UTILITY(U,$J,358.3,13233,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13233,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,13233,1,8,0)
 ;;=8^Unspec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,13233,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,13234,0)
 ;;=238.72^^83^834^14
 ;;^UTILITY(U,$J,358.3,13234,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13234,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,13234,1,8,0)
 ;;=8^Low Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,13234,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,13235,0)
 ;;=238.73^^83^834^12
 ;;^UTILITY(U,$J,358.3,13235,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13235,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,13235,1,8,0)
 ;;=8^Hi Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,13235,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,13236,0)
 ;;=238.75^^83^834^15
 ;;^UTILITY(U,$J,358.3,13236,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13236,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,13236,1,8,0)
 ;;=8^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,13236,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,13237,0)
 ;;=205.00^^83^835^32
 ;;^UTILITY(U,$J,358.3,13237,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13237,1,1,0)
 ;;=1^205.00
 ;;^UTILITY(U,$J,358.3,13237,1,8,0)
 ;;=8^Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,13237,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,13238,0)
 ;;=205.01^^83^835^31
 ;;^UTILITY(U,$J,358.3,13238,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13238,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,13238,1,8,0)
 ;;=8^Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,13238,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,13239,0)
 ;;=205.10^^83^835^18
 ;;^UTILITY(U,$J,358.3,13239,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13239,1,1,0)
 ;;=1^205.10
 ;;^UTILITY(U,$J,358.3,13239,1,8,0)
 ;;=8^Chr Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,13239,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,13240,0)
 ;;=205.11^^83^835^17
 ;;^UTILITY(U,$J,358.3,13240,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13240,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,13240,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,13240,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,13241,0)
 ;;=289.0^^83^835^50
 ;;^UTILITY(U,$J,358.3,13241,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13241,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,13241,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,13241,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,13242,0)
 ;;=238.4^^83^835^48
 ;;^UTILITY(U,$J,358.3,13242,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13242,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,13242,1,8,0)
 ;;=8^Polycythemia Rubra Vera
 ;;^UTILITY(U,$J,358.3,13242,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,13243,0)
 ;;=288.9^^83^835^67
 ;;^UTILITY(U,$J,358.3,13243,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13243,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,13243,1,8,0)
 ;;=8^Unspecified Dis Of W B C
 ;;^UTILITY(U,$J,358.3,13243,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,13244,0)
 ;;=289.81^^83^835^49
 ;;^UTILITY(U,$J,358.3,13244,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13244,1,1,0)
 ;;=1^289.81
 ;;^UTILITY(U,$J,358.3,13244,1,8,0)
 ;;=8^Primary Hypercoagulable State
 ;;^UTILITY(U,$J,358.3,13244,2)
 ;;=^329886
 ;;^UTILITY(U,$J,358.3,13245,0)
 ;;=238.75^^83^835^29
 ;;^UTILITY(U,$J,358.3,13245,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13245,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,13245,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,13245,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,13246,0)
 ;;=289.9^^83^835^66
 ;;^UTILITY(U,$J,358.3,13246,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13246,1,1,0)
 ;;=1^289.9
 ;;^UTILITY(U,$J,358.3,13246,1,8,0)
 ;;=8^Unspecified Blood Disease
 ;;^UTILITY(U,$J,358.3,13246,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,13247,0)
 ;;=205.02^^83^835^30
 ;;^UTILITY(U,$J,358.3,13247,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13247,1,1,0)
 ;;=1^205.02
 ;;^UTILITY(U,$J,358.3,13247,1,8,0)
 ;;=8^Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,13247,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,13248,0)
 ;;=205.12^^83^835^16
 ;;^UTILITY(U,$J,358.3,13248,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13248,1,1,0)
 ;;=1^205.12
 ;;^UTILITY(U,$J,358.3,13248,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,13248,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,13249,0)
 ;;=205.20^^83^835^59
 ;;^UTILITY(U,$J,358.3,13249,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13249,1,1,0)
 ;;=1^205.20
 ;;^UTILITY(U,$J,358.3,13249,1,8,0)
 ;;=8^Subacute Myeloid Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,13249,2)
 ;;=^336857
 ;;^UTILITY(U,$J,358.3,13250,0)
 ;;=205.21^^83^835^58
 ;;^UTILITY(U,$J,358.3,13250,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13250,1,1,0)
 ;;=1^205.21
 ;;^UTILITY(U,$J,358.3,13250,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,13250,2)
 ;;=^267536
 ;;^UTILITY(U,$J,358.3,13251,0)
 ;;=205.22^^83^835^57
 ;;^UTILITY(U,$J,358.3,13251,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13251,1,1,0)
 ;;=1^205.22
 ;;^UTILITY(U,$J,358.3,13251,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,13251,2)
 ;;=^336472
 ;;^UTILITY(U,$J,358.3,13252,0)
 ;;=205.30^^83^835^35
 ;;^UTILITY(U,$J,358.3,13252,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13252,1,1,0)
 ;;=1^205.30
 ;;^UTILITY(U,$J,358.3,13252,1,8,0)
 ;;=8^Myeloid Sarcoma w/o Remission
 ;;^UTILITY(U,$J,358.3,13252,2)
 ;;=^336858
 ;;^UTILITY(U,$J,358.3,13253,0)
 ;;=205.31^^83^835^34
 ;;^UTILITY(U,$J,358.3,13253,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13253,1,1,0)
 ;;=1^205.31
 ;;^UTILITY(U,$J,358.3,13253,1,8,0)
 ;;=8^Myeloid Sarcoma in Remission
 ;;^UTILITY(U,$J,358.3,13253,2)
 ;;=^267538
 ;;^UTILITY(U,$J,358.3,13254,0)
 ;;=205.32^^83^835^33
 ;;^UTILITY(U,$J,358.3,13254,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13254,1,1,0)
 ;;=1^205.32
 ;;^UTILITY(U,$J,358.3,13254,1,8,0)
 ;;=8^Myeloid Sarcoma in Relapse
 ;;^UTILITY(U,$J,358.3,13254,2)
 ;;=^336473
 ;;^UTILITY(U,$J,358.3,13255,0)
 ;;=205.80^^83^835^44
 ;;^UTILITY(U,$J,358.3,13255,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13255,1,1,0)
 ;;=1^205.80
 ;;^UTILITY(U,$J,358.3,13255,1,8,0)
 ;;=8^Oth Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,13255,2)
 ;;=^336859
 ;;^UTILITY(U,$J,358.3,13256,0)
 ;;=205.81^^83^835^43
 ;;^UTILITY(U,$J,358.3,13256,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13256,1,1,0)
 ;;=1^205.81
 ;;^UTILITY(U,$J,358.3,13256,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,13256,2)
 ;;=^267540
 ;;^UTILITY(U,$J,358.3,13257,0)
 ;;=205.82^^83^835^42
 ;;^UTILITY(U,$J,358.3,13257,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13257,1,1,0)
 ;;=1^205.82
 ;;^UTILITY(U,$J,358.3,13257,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,13257,2)
 ;;=^336474
 ;;^UTILITY(U,$J,358.3,13258,0)
 ;;=205.90^^83^835^65
 ;;^UTILITY(U,$J,358.3,13258,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13258,1,1,0)
 ;;=1^205.90
 ;;^UTILITY(U,$J,358.3,13258,1,8,0)
 ;;=8^Unspec Myeloid Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,13258,2)
 ;;=^336860
 ;;^UTILITY(U,$J,358.3,13259,0)
 ;;=205.91^^83^835^64
 ;;^UTILITY(U,$J,358.3,13259,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13259,1,1,0)
 ;;=1^205.91
 ;;^UTILITY(U,$J,358.3,13259,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Remission
 ;;^UTILITY(U,$J,358.3,13259,2)
 ;;=^267542
 ;;^UTILITY(U,$J,358.3,13260,0)
 ;;=205.92^^83^835^63
 ;;^UTILITY(U,$J,358.3,13260,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13260,1,1,0)
 ;;=1^205.92
 ;;^UTILITY(U,$J,358.3,13260,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,13260,2)
 ;;=^336475
 ;;^UTILITY(U,$J,358.3,13261,0)
 ;;=206.00^^83^835^6
 ;;^UTILITY(U,$J,358.3,13261,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13261,1,1,0)
 ;;=1^206.00
 ;;^UTILITY(U,$J,358.3,13261,1,8,0)
 ;;=8^Acute Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,13261,2)
 ;;=^336861
 ;;^UTILITY(U,$J,358.3,13262,0)
 ;;=206.01^^83^835^5
 ;;^UTILITY(U,$J,358.3,13262,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13262,1,1,0)
 ;;=1^206.01
 ;;^UTILITY(U,$J,358.3,13262,1,8,0)
 ;;=8^Acute Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,13262,2)
 ;;=^267544
 ;;^UTILITY(U,$J,358.3,13263,0)
 ;;=206.02^^83^835^4
 ;;^UTILITY(U,$J,358.3,13263,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13263,1,1,0)
 ;;=1^206.02
 ;;^UTILITY(U,$J,358.3,13263,1,8,0)
 ;;=8^Acute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,13263,2)
 ;;=^336476
 ;;^UTILITY(U,$J,358.3,13264,0)
 ;;=206.10^^83^835^15
 ;;^UTILITY(U,$J,358.3,13264,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13264,1,1,0)
 ;;=1^206.10
 ;;^UTILITY(U,$J,358.3,13264,1,8,0)
 ;;=8^Chr Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,13264,2)
 ;;=^336862
 ;;^UTILITY(U,$J,358.3,13265,0)
 ;;=206.11^^83^835^14
 ;;^UTILITY(U,$J,358.3,13265,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13265,1,1,0)
 ;;=1^206.11
 ;;^UTILITY(U,$J,358.3,13265,1,8,0)
 ;;=8^Chr Monocytic Leuk in Remission
